Osimertinib

Acquired resistance: case report

    Reactions Weekly volume 1841, page202(2021)Cite this article

    This is a preview of subscription content, access via your institution.

    Access options

    Buy single article

    Instant access to the full article PDF.

    US$ 49.95

    Tax calculation will be finalised during checkout.

    Reference

    1. Sun Y, et al. A novel myh9-ret fusion occurrence and EGFR T790M loss as an acquired resistance mechanism to osimertinib in a patient with lung adenocarcinoma: A case report. OncoTargets and Therapy 13: 11177-11181, 2 Nov 2020. Available from: URL: http://doi.org/10.2147/OTT.S267524

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Osimertinib. Reactions Weekly 1841, 202 (2021). https://doi.org/10.1007/s40278-021-90704-y

    Download citation